Inhibition of extracellular vesicle pathway using neutral sphingomyelinase inhibitors as a neuroprotective treatment for brain injury

作     者：Asit Kumar Santosh Kumar Asit Kumar;Santosh Kumar

作者机构：Department of Pharmaceutical SciencesUniversity of Tennessee Health Science CenterMemphisTNUSA 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2021年第16卷第12期

页      面：2349-2352页

核心收录：

学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学] 

基　　金：This work was in part supported by the Plough Center for Sterile Drug Delivery Solution at the University of Tennessee Health Science Center(to SK) 

主　　题：brain injury ceramide extracellular vesicles microglia neuroinflammation neuroprotection neutral sphingomyelinase 

摘      要：Traumatic brain injury is a sudden trauma or blow on the head,and severe traumatic brain injury is a major cause of death and disability *** acute and chronic consequences following traumatic brain injury can lead to progressive secondary neurodegenerative changes and cognitive *** date,there is no effective pharmaceutical products for the treatment to reduce secondary damage after brain *** discovery of extracellular vesicles has attracted considerable scientific attention due to their role in cell-to-cell *** vesicles have shown their potential to carry not only biological molecules but also as a drug delivery *** a carrier of molecular information,extracellular vesicles have been involved in physiological functions as well as in the modulation of immune ***,we aim to provide new insights into the contrasting role of extracellular vesicles in the propagation of inflammatory responses after brain *** a carrier of pro-inflammatory molecules,their role as functional mediators in the pathophysiology of brain injury is discussed,addressing the inhibition of the extracellular vesicle pathway as an anti-inflammatory or neuroprotective approach to improve the outcome of both acute and chronic inflammation following brain ***,we summarize therapeutic strategies to diminish the risk the neurodegeneration post brain injury and propose that neutral sphingomyelinase inhibitors could be used as potentially useful therapeutic agents for the treatment of brain injury associated neuroinflammation.